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DObjective: Patients with rheumatoid arthritis have an increased risk for accelerated arthrosclerosis. It is not
known, however, whether this disorder is associated with a higher risk of complications after coronary artery
revascularization.
Methods: We conducted a cross-sectional study of patients in the 2003–2005 Nationwide Inpatient Sample. To
determine whether patients with rheumatoid arthritis had higher in-hospital mortality after coronary artery revas-
cularization, we used logistic regression to adjust for age, sex, race/ethnicity, income, rural–urban residency,
diabetes, hypertension, hyperlipidemia, Charlson comorbidities (including myocardial infarction, congestive
heart failure, and diabetes), elective admission, weekend admission, and primary payer.
Results: Among patients undergoing coronary artery revascularization, those with rheumatoid arthritis were
49% less likely to die while hospitalized compared with those without rheumatoid arthritis (odds ratio, 0.51;
95% confidence interval, 0.40–0.65) after adjusting for the above confounders. In subgroup analyses that
adjusted for the same confounders, patients with rheumatoid arthritis also had a 61% improvement of in-patient
mortality when they underwent percutaneous coronary interventions (odds ratio, 0.39; 95% confidence interval,
0.29–0.54) along with a median of 0.32 less days hospitalized (95% confidence interval, 0.28–0.34 days).
Similarly, patients with rheumatoid arthritis undergoing coronary artery bypass grafting had a 31% improvement
of in-patient mortality (odds ratio, 0.69; 95% confidence interval, 0.48–0.99), with a median of 1.36 less days
hospitalized (95% confidence interval, 0.72–1.12 days).
Conclusion: Among patients undergoing coronary artery revascularization, patients with rheumatoid arthritis
have an in-hospital survival advantage along with reduced days of hospitalization compared with patients without
rheumatoid arthritis. (J Thorac Cardiovasc Surg 2010;140:91-6)Patients with rheumatoid arthritis (RA) are predisposed to
accelerated atherosclerosis.1 Moreover, cardiovascular
disease is the leading cause of mortality among patients
with RA.2,3 Both traditional and nontraditional cardiovas-
cular risk factors contribute to increased atherogenicity in
patients with RA.4,5 There are, moreover, additional factors
that occur more frequently in patients with RA that might
contribute to increased mortality, such as increased fre-
quency of diffuse multivessel coronary artery disease,6 in-
creased frequency of microvascular coronary artery
disease,6 systemic inflammation,7 and a disparity in the
quality of care for coronary artery disease delivered to pa-
tients with RA.8 Patients with RA are also more likely to
have wound-healing problems and infections, includinge Department of Medicinea and the Division of Rheumatology,b Southern
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The Journal of Thoracic and Csepsis. Some of these same factors could also adversely
influence the success of coronary artery revascularization
procedures.
Percutaneous coronary interventions (PCIs) and coronary
artery bypass grafting (CABG) are the 2 main revasculariza-
tion strategies for patients with coronary artery disease. The
relative frequency and efficacy of these procedures have not
been studied in patients with RA. Despite a higher risk for
cardiovascular mortality in patients with RA, prior studies
have not used RA in models to predict in-hospital mortality
in patients undergoing PCI or CABG.9–11 Because RA is
a risk factor for coronary artery disease, we hypothesized
that patients with RA who undergo coronary revasculariza-
tion procedures would have higher in-hospital mortality
compared with that seen in patients without RA. As second-
ary analyses, we performed subgroup analyses of in-hospital
mortality, length of stay, and total hospital charges in
patients who underwent either PCI or CABG.MATERIALS AND METHODS
Study Population
We obtained deidentified data from the Nationwide Inpatient Sample
(NIS) through the Agency for Healthcare Research and Quality after insti-
tutional review board approval. NIS is a stratified probability sample of state
inpatient databases and is the largest all-payer database in the United States.ardiovascular Surgery c Volume 140, Number 1 91
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
NIS ¼ Nationwide Inpatient Sample
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
RA ¼ rheumatoid arthritis
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than 1000 hospitals (approximately 20% of all hospitals) in 37 states.
Study End Points
The outcome measure of interest was in-hospital mortality. For second-
ary analysis, we separately evaluated in-hospital mortality in patients under-
going PCI with and without stent placement and CABG. We also evaluated
length of stay and total hospital charges in the PCI and CABG subgroups.
The total hospital charges represent cleared charges that do not include
professional fees and noncovered charges.
Study Exposure
For our study population, we selected patients who had undergone coro-
nary artery revascularization with International Classification of Diseases,
Ninth Edition, Clinical Modification procedure codes: CABG (36.10–36.19)
or PCI (36.01–36.09 and 00.66 for 2005). Among those patients who had
undergone coronary artery revascularization, we identified patients with RA
by using Clinical Modification codes (7140, 7141, and 7142).
Patient Characteristics
We determined baseline characteristics that are most likely present at
hospital admission for patients with RA. Those patients without RA
were considered the control group for our analysis. Baseline characteris-
tics included age, sex, race/ethnicity, quartile income, rural–urban resi-
dency, and primary payer for the hospitalization. We used CM codes
based on hospital discharge diagnoses to determine the presence of addi-
tional known risk factors for atherosclerosis that were available in this
database: diabetes, hypertension, and hyperlipidemia. To assess comorbid-
ities, we also used hospital discharge diagnoses to calculate the Deyo
modification of the Charlson comorbidity index,12 which includes such
conditions as acute myocardial infarction, congestive heart failure, periph-
eral vascular disease, and diabetes. We performed an additional analysis
with the Elixhauser comorbidities.13 We also assessed whether patients
were admitted electively and whether patients were admitted on a weekend
or a weekday.
Statistical Analysis
Baseline characteristics were analyzed by using either the Fisher’s exact
test for discrete data or the t test for continuous data. For our analysis of in-
hospital mortality, we used logistic regression to adjust for baseline charac-
teristics. Our final model included age, age squared, sex, race/ethnicity,
quartile income, rural–urban residency, hypertension, hyperlipidemia,
Charlson comorbidity index, elective versus nonelective admission, week-
end versus weekday admission, and primary payer. Multiple imputations
were used for missing data, but the final model was additionally tested
among patients including only those who had complete information for
all variables. For our analysis of length of stay, we used linear regression
on log-transformed length of stay and adjusted for the same confounding
variables. Similar log-transformations were used to analyze total hospital
charges.92 The Journal of Thoracic and Cardiovascular SurgeBecause arthritis is used in the calculation of the Charlson comorbidity
index, all patients with RA will have a Charlson index score of at least 1.
We therefore did sensitivity analyses to determine whether this factor
affected the outcome. For our first sensitivity analysis, we collapsed index
scores of 0 and 1 such that all patients had a Charlson comorbidity index
of at least 1. For our second sensitivity analysis, we subtracted 1 from the
comorbidity index for patients with RA to remove these factors from the
Charlson comorbidity index. For our third sensitivity analysis, we per-
formed a separate analysis with Elixhauser comorbidities with the same sec-
ondary adjustments as done for the Charlson comorbidity index.
Statistical analysis was performed with SAS 9.1 (SAS Institute, Inc,
Cary, NC) and SUDAAN 9.0 (Research Triangle Institute, Research Trian-
gle Park, NC) software. We used a 2-sided P value of less than .05 to assess
statistical significance for baseline characteristics of the study population
and 95% confidence intervals (CIs) for all other analyses.RESULTS
Characteristics of the Study Population
We identified 680,479 patients who underwent coronary
artery revascularization. RA was diagnosed in 5485
(0.8%) patients. Among patients who underwent any type
of coronary artery revascularization, there were differences
in all baseline characteristics between patients with RA
and control subjects (Table 1). For instance, patients with
RA who underwent coronary artery revascularization were
older and more likely white. They were more likely to
have hypertension but less likely to have diabetes or hyper-
lipidemia. They were also more likely admitted on an emer-
gency basis and during weekends.Multivariable Analysis
Among patients who underwent coronary artery revascu-
larization, patients with RA were overall equally likely to die
while hospitalized compared with patients without RA
(Table 2). We then used logistic regression analysis to deter-
mine the effect of RA itself on in-hospital mortality after
controlling for confounding variables that are associated
with RA. In this analysis patients with RA were 49% less
likely to die while hospitalized compared with those in the
control group (odds ratio [OR], 0.51; 95% CI, 0.40–0.65)
after adjusting for age, sex, race/ethnicity, quartile income,
rural–urban residency, hypertension, hyperlipidemia, Charl-
son comorbidity index (including myocardial infarction,
congestive heart failure, diabetes, and peripheral vascular
disease), elective admission, weekend admission, and
primary payer (Table 2). This finding is not explained by
a single variable; patients with RA had improved survival
when each variable was sequentially removed from the
model (data not shown). In separate analyses we obtained
similar results with the first 2 categories of the Charlson
index collapsed, with the elimination of arthritis from the
Charlson index for patients with RA, with the use of Elix-
hauser rather than Charlson comorbidities, and with patients
limited to those who had complete information for all
variables (data not shown).ry c July 2010
TABLE 1. Characteristics of the study population*
All revascularized patients Patients receiving only PCI Patients receiving only CABG
Baseline characteristic Control group Rheumatoid arthritis P valuey Control group Rheumatoid arthritis P valuey Control group Rheumatoid arthritis P Valuey
No. (%) 674,994 (99.2) 5485 (0.8) 483,615 (99.2) 3974 (0.8) 185,919 (99.2) 1463 (0.8)
Age, y (SD) 64.8 (12.0) 67.0 (10.6) <.001 64.4 (12.3) 66.8 (10.9) <.001 66.0 (10.9) 67.5 (9.6) <.001
Female sex, n (%) 219,412 (32.5) 2941 (53.6) <.001 163,752 (33.9) 2251 (56.7) <.001 54,009 (29.0) 669 (45.8) <.001
Race, n (%) <.001 <.001 .004
White 386,055 (81.6) 3265 (85.3) 274,914 (81.6) 2320 (85.0) 107,990 (81.6) 919 (86.0)
Black 30,510 (6.4) 250 (6.5) 22,381 (6.6) 190 (7.0) 7927 (6.0) 58 (5.4)
Hispanic 31,690 (6.7) 187 (4.9) 22,268 (6.6) 134 (4.9) 9135 (6.9) 51 (4.8)
Asian 8919 (1.9) 43 (1.1) 5990 (1.8) 29 (1.1) 2862 (2.2) 14 (1.3)
Other 14,946 (3.2) 76 (2.0) 10,677 (3.2) 51 (1.9) 4148 (3.1) 23 (2.2)
Quartile income, n (%) <.001 .002 .13
0%–25% 164,738 (25.0) 1266 (23.7) 117,120 (24.8) 901 (23.2) 46,267 (25.5) 349 (24.6)
26%–50% 172,905 (26.3) 1538 (28.8) 122,677 (26.0) 1101 (28.4) 48,883 (27.0) 422 (29.7)
51%–75% 167,261 (25.4) 1367 (25.6) 120,160 (25.5) 1007 (26.0) 45,720 (25.2) 353 (24.9)
76%–100% 153,495 (23.3) 1178 (22.0) 112,010 (23.7) 872 (22.5) 40,267 (22.2) 296 (20.8)
Rural–urban, n (%) <.001 <.001 <.001
Large metropolitan area 334,140 (49.7) 2463 (45.1) 243,462 (50.6) 1833 (46.3) 88,211 (47.7) 612 (42.0)
Small metropolitan area 201,167 (30.0) 1812 (33.2) 141,556 (29.4) 1301 (32.8) 57,745 (31.2) 492 (33.7)
Micropolitan area 77,195 (11.5) 656 (12.0) 54,500 (11.3) 449 (11.3) 22,097 (12.0) 200 (13.7)
Nonurban 59,232 (8.8) 535 (9.8) 41,906 (8.7) 377 (9.5) 16,832 (9.1) 154 (10.6)
Hypertension, n (%) 433,481 (64.2) 3629 (66.2) .003 306,865 (63.4) 2626 (66.1) <.001 123,465 (66.4) 971 (66.4) .98
Hyperlipidemia, n (%) 366,099 (54.2) 2795 (51.0) <.001 270,472 (55.9) 2034 (51.2) <.001 93,252 (50.2) 738 (50.4) .83
Charlson score, n (%) <.001 <.001 <.001
0 184,731 (27.4) 0 (0) 138,620 (28.7) 0 (0) 45,529 (24.5) 0 (0)
1 266,716 (39.5) 1324 (24.1) 197,843 (40.9) 956 (24.1) 66,657 (35.8) 359 (24.5)
2 143,439 (21.2) 2288 (41.7) 96,875 (20.0) 1696 (42.7) 44,897 (24.2) 562 (38.4)
3 55,423 (8.2) 1208 (22.0) 34,722 (7.2) 858 (21.6) 19,975 (10.7) 346 (23.6)
4 17,230 (2.6) 469 (8.6) 10,599 (2.2) 318 (8.0) 6419 (3.4) 149 (10.2)
5 7455 (1.1) 196 (3.6) 4956 (1.0) 146 (3.7) 2442 (1.3) 47 (3.2)
Elective admission, n (%) 266,804 (39.6) 1890 (34.5) <.001 175,765 (36.4) 1175 (29.6) <.001 89,678 (48.3) 704 (48.1) .90
Weekend admission, n (%) 79,744 (11.8) 732 (13.4) <.001 60,235 (12.5) 578 (14.5) <.001 18,497 (10.0) 148 (10.1) .83
Primary payer, n (%) <.001 <.001 <.001
Medicare 352,945 (52.4) 3569 (65.2) 247,668 (51.3) 2589 (65.2) 102,678 (55.3) 951 (65.1)
Medicaid 31,602 (4.7) 206 (3.8) 22,981 (4.8) 153 (3.8) 8341 (4.5) 50 (3.4)
Private 248,432 (36.8) 1547 (28.2) 182,058 (37.7) 1110 (28.0) 64,243 (34.6) 422 (28.9)
Self-pay 22,325 (3.3) 59 (1.1) 16,884 (3.5) 42 (1.1) 5198 (2.8) 17 (1.2)
Other 16,600 (2.5) 89 (1.6) 11,860 (2.5) 70 (1.8) 4560 (2.5) 18 (1.2)
PCI, Percutaneous coronary intervention; CABG, coronary artery bypass grafting; SD, standard deviation. *Some baseline characteristics were eliminated from the table because of cell numbers less than 10. yPatients with rheumatoid
arthritis compared with the control group.
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TABLE 2. In-hospital mortality
OR for in-hospital mortality:
patients with RA compared
with control subjects
Procedure
Unadjusted OR
(95% CI)
Adjusted* OR
(95% CI)
Any revascularization 0.87 (0.69–1.09) 0.51 (0.40–0.65)
CABG only 0.89 (0.62–1.26) 0.69 (0.48–0.99)
PCI only 0.78 (0.57–1.07) 0.39 (0.29–0.54)
PCI only with stent 0.79 (0.56–1.11) 0.40 (0.28–0.56)
PCI only without stent 0.77 (0.32–1.86) 0.37 (0.15–0.93)
OR, Odds ratio; RA, rheumatoid arthritis; CI, confidence interval; CABG, coronary
artery bypass grafting; PCI, Percutaneous coronary intervention. *Adjusted for age,
age squared, sex, race/ethnicity, quartile income, rural–urban residency, hypertension,
hyperlipidemia, Charlson comorbidity index, elective admission, weekend admission,
and primary payer.
TABLE 3. Length of stay
Change in length of stay (d):
patients with RA compared
with control subjects
Procedure
Unadjusted median
(95% CI)
Adjusted median*
(95% CI)
Any revascularization 0.24 (0.15 to 0.30) 0.57 (0.54 to0.63)
CABG only 0.48 (0.32 to0.72) 1.36 (1.12 to0.72)
PCI only 0.30 (0.24 to 0.36) 0.32 (0.28 to0.34)
PCI only with stent 0.32 (0.26 to 0.36) 0.30 (0.26 to0.32)
PCI only without stent 0.26 (0.04 to 0.52) 0.38 (0.22 to0.52)
RA, Rheumatoid arthritis;CI, confidence interval;CABG, coronary artery bypass graft-
ing; PCI, Percutaneous coronary intervention. *Adjusted for age, age squared, sex,
race/ethnicity, quartile income, rural–urban residency, hypertension, hyperlipidemia,
Charlson comorbidity index, elective admission, weekend admission, and primary
payer.
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tion, patients with RA were 23% more likely (adjusted
OR, 1.23; 95% CI, 1.15–1.32) than the control group to
undergo PCI rather than CABG. As a subgroup analysis,
we separately evaluated in-hospital mortality in patients
who underwent PCI and in patients who underwent
CABG. Patients with RA were 61% less likely to die while
hospitalized compared with the control group after PCI
(adjusted OR, 0.39; 95% CI, 0.29–0.54). This improved
mortality was seen irrespective of whether patients had cor-
onary artery stents placed (Table 2). Similarly, patients with
RA were 31% less likely to die while hospitalized after
CABG (adjusted OR, 0.69; 95% CI, 0.48–0.99; Table 2).
For patients undergoing PCI, the hospital length of stay
was 0.32 days shorter (95% CI, 0.28–0.34 days) for patients
with RA compared with the control group after adjusting for
the same confounders (Table 3), with a median savings in
total hospital charges of $3391 (95% CI, $2638–$4145; Ta-
ble 4). For patients undergoing PCI, improvements were
also seen irrespective of whether patients had coronary
artery stents placed (Tables 3 and 4). Similarly, for patients
undergoing CABG, the length of stay was 1.36 days shorter
(95% CI, 0.72–1.12 days) for patients with RA, with
a median savings in total hospital charges of $12,535
(95% CI, $10,323–$14,010).DISCUSSION
Because RA is a risk factor for the development of coro-
nary artery disease, because myocardial infarctions are the
leading cause of mortality in patients with RA, and because
patients with RA have more microvascular disease, we an-
ticipated that patients with RA who underwent coronary
revascularization procedures would have higher in-hospital
mortality compared with that seen among patients without
these underlying disorders. Paradoxically, we found the
opposite. Among patients who underwent coronary artery
revascularization, patients with RA were 49% less likely94 The Journal of Thoracic and Cardiovascular Surgeto die while hospitalized compared with patients without
these conditions after adjusting for confounders. For patients
with RA, this improvement was also seen in patients under-
going either PCI or CABG. Consistent with the primary
observation, patients with RA had improved outcomes
beyond in-hospital mortality as well. Compared with the
control group, patients with RA undergoing either PCI or
CABG had shorter lengths of stay and reduced total hospital
charges after adjusting for confounders.
RA is now considered an independent risk factor for
coronary artery disease,14 and chronic systemic inflamma-
tion is now understood to play a pivotal role in the develop-
ment of accelerated atherosclerosis in patients with RA.15
Thus it is difficult to explain why a risk factor for the devel-
opment of atherosclerosis would be associated with
improved in-hospital mortality after coronary artery revas-
cularization. These results cannot be explained by the age
of these patients or their comorbid conditions because we
adjusted for these confounders in our analysis. Moreover,
the protective effect of RA remained when we included or
excluded arthritis as a comorbid condition in calculating
the Charlson or Elixhauser comorbidity indexes.
There is precedence for the paradoxic observation that
a risk factor can be associated with improved mortality.
Although hyperlipidemia is a risk factor for atherosclerosis,
for example, it has also been found to be associated with
improved in-hospital mortality.16 Therefore it is tempting
to speculate that in patients with RA, there might be some
difference in their atherosclerotic lesions, in their physio-
logic response to atherosclerotic lesions, or in their ability
to heal after coronary artery revascularization procedures.
Such differences might then lead to improvement in their
clinical outcome after coronary artery revascularization. It
is also interesting to note that prior studies demonstrated
that statin pretreatment in patients undergoing coronary
artery revascularization was associated with decreased risk
of periprocedural myocardial infarction and long-term mor-
tality.17,18 Moreover, C-reactive protein levels were reducedry c July 2010
TABLE 4. Total hospital charges
Differences in total hospital charges (US$):
patients with RA compared
with control subjects
Procedure
Unadjusted median
(95% CI)
Adjusted median*
(95% CI)
Any revascularization 900 (0 to1400) 6300 (5400 to6800)
CABG only 8100 (5900 to
10,300)
12,500 (10,300 to
14,000)
PCI only 1100 (400 to 1900) 3400 (2600 to4100)
PCI only with stent 1000 (300 to 1600) 2600 (1900 to3200)
PCI only without
stent
1400 (4200 to 1900) 4600 (4200 to9100)
RA, Rheumatoid arthritis;CI, confidence interval;CABG, coronary artery bypass graft-
ing; PCI, Percutaneous coronary intervention. *Adjusted for age, age squared, sex,
race/ethnicity, quartile income, rural-urban residency, hypertension, hyperlipidemia,
Charlson comorbidity index, elective admission, weekend admission, and primary
payer.
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effects of statins might be mediated through control of
inflammation. Disease-modifying agents for RA, such as
methotrexate and tumor necrosis factor a inhibitors, also
decrease C-reactive protein levels and more recently have
been observed to decrease the risk for cardiovascular disease
in these patients.19–21 It is tempting to speculate that patients
with RA receive more aggressive treatment for inflammation
than patients without these disorders and that this treatment
to reduce inflammation might lead to the improved outcome
compared with that seen in control subjects when they
undergo coronary artery revascularization.
Inflammation in cardiac surgical patients is regulated by
complex humoral and cellular interactions, including activa-
tion, generation, or enhanced expression of thrombin, com-
plement, cytokines, neutrophils, adhesion molecules, mast
cells, and other inflammatory mediators.22,23 Both proin-
flammatory and anti-inflammatory cytokines are produced
during cardiopulmonary bypass. Multiple mediations and
leukocyte depletion filters have been tried to attenuate the
effects of these inflammatory cytokines. Although results
have been variable, one study suggests that reducing
CABG-influenced inflammation might reduce myocardial
reperfusion injuries.24 Thus it is possible that the immuno-
suppression used in patients with RA might decrease postop-
erative complications in these patients, although there is no
evidence to substantiate this hypothesis. Moreover, other
mechanisms are involved because there are similar improve-
ments in patients undergoing PCI.
Our results appear to differ from those of Van Doornum
and colleagues,25 who reported that patients with RA had
a higher 30-day mortality rate after their first myocardial
infarction. This difference in mortality is likely explained
by differences in the design of these studies. Using adminis-
trative databases from Australia, they studied a differentThe Journal of Thoracic and Cpopulation of patients, those who were hospitalized for their
first myocardial infarction irrespective of whether they
underwent coronary artery revascularization, whereas we
analyzed all patients undergoing coronary artery revascular-
ization irrespective of whether they had a myocardial infarc-
tion. Their end point was 30-day mortality, although they
indicated that the majority of deaths occurred while patients
were hospitalized. Both studies were observational, and
therefore differences could potentially be explained by dif-
ferent patterns of practice for the selection of revasculariza-
tion compared with medical therapy or even different
patterns of treatment for RA. Indeed, in their population of
patients, the adjusted OR to undergo PCI for patients with
RA compared with that for patients without RA was 0.5
(95% CI, 0.3–0.8), whereas in our population the adjusted
OR to undergo PCI for patients with RA compared with
that seen in the control group was 1.23 (95%CI, 1.15–1.32).
There are some important limitations to our study.
Because NIS is an administrative database, there will be
inaccuracies in the diagnosis and coding of RA, as well as
other comorbid conditions. Because there is no reason to
suspect a systematic bias with coding or miscoding these
disorders, these inaccuracies should therefore bias the results
toward the null hypothesis. More importantly, this is an
observational study from an administrative database and
not a randomized trial, and therefore there is the possibility
that unmeasured factors could influence the outcome. We
cannot, for instance, adjust for use of medications, the extent
of coronary artery disease, and ventricular function. Thus
even though the data are suggestive, we cannot conclude
that RA would have a protective effect on in-hospital mortal-
ity if patients were randomized. Indeed, physicians selected
patients for PCI and CABG based on their opinion that these
procedures would provide the best outcome for their
patients. Because it is unlikely that we will ever have a ran-
domized clinical trial to address the hypothesis of this study,
it is reassuring to note that the current use of coronary artery
revascularization for patients with RA in the United States
appears beneficial. These results further suggest that there
should not be undo concern about considering coronary
artery revascularization in patients with these underlying
disorders.
Despite these limitations, the finding that patients with
RA undergoing coronary revascularization procedures
have decreased in-hospital mortality compared with that
seen in control subjects is, although surprising, provocative
and should engender further investigation. Further studies
are needed to confirm the dissociation in a risk factor for
the development of a disease from its association with
improved clinical outcomes, in this case patients with RA
undergoing coronary artery revascularization. Such studies
might not only help us better understand the pathogenesis
of such disorders but also provide additional clues for
successful therapy.ardiovascular Surgery c Volume 140, Number 1 95
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